Loading stock data…
$24.40-1.43 (-5.54%)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Viking Therapeutics, Inc. in the Healthcare sector is trading at $24.40 with a market capitalization of $4.0B. Wall Street consensus targets $95.05 (19 analysts), implying a +289.6% move over the next 12 months. The stock is currently near its 52-week low of $24.36, remaining 25.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$132.60M↑ | -$164.13M↑ | -$164.74M↓ | -$98.56M↓ | -$74.57M |
| Net Income | -$128.02M↑ | -$158.32M↓ | -$157.66M↓ | -$90.79M↓ | -$65.56M |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective a...